A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib,

Introduction

Establishment of MET Exon 14 Splice Site Mutations (Metex14+) as an Actionable Driver Mutation in Non-Small Cell Lung Cancer (NSCLC)

The receptor tyrosine kinase (RTK) Mesenchymal Epithelial Transition (MET) is one of the 58 human…